Journal
NANOMEDICINE
Volume 16, Issue 10, Pages 857-877Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2020-0482
Keywords
Amphotericin B; drug delivery systems; fungal infections; Leishmania infection; nanotechnology
Ask authors/readers for more resources
Research has shown that nano-based systems can improve the therapeutic effects of Amphotericin B and reduce its toxicities, but commercial lipid formulations are limited in use due to their high cost.
Amphotericin B (AMB), with widespread antifungal and anti-parasitic activities and low cross-resistance with other drugs, has long been identified as a potent antimicrobial drug. However, its clinical toxicities, especially nephrotoxicity, have limited its use in clinical practice. Lately, nano-based systems have been the subject of serious research and becoming an effective strategy to improve toxicity and antimicrobial potency. Commercial AMB lipid formulations have been developed in order to improve the therapeutic index and nephrotoxicity, while limited use is mainly due to their high cost. The review aimed to highlight the updated information on nanotechnology-based approaches to the development of AMB delivery and targeting systems for treatment of fungal diseases and leishmaniasis, regarding therapeutic challenges and achievements of various delivery systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available